Aminoglycosides for Treatment of Bacteremia Due to Carbapenem-Resistant Klebsiella pneumoniae | Zendy

Ryan K. Shields | Zendy; Cornelius J. Clancy | Zendy; Ellen G. Press | Zendy; M. Hong Nguyen | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Aminoglycosides for Treatment of Bacteremia Due to Carbapenem-Resistant Klebsiella pneumoniae

Author(s) -

Ryan K. Shields,

Cornelius J. Clancy,

Ellen G. Press,

M. Hong Nguyen

Publication year - 2016

Publication title -

antimicrobial agents and chemotherapy

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.07

H-Index - 259

eISSN - 1070-6283

pISSN - 0066-4804

DOI - 10.1128/aac.02638-15

Subject(s) - klebsiella pneumoniae , bacteremia , aminoglycoside , medicine , antibiotics , carbapenem , pharmacokinetics , intensive care medicine , klebsiella , microbiology and biotechnology , biology , escherichia coli , biochemistry , gene

Aminoglycoside treatment of carbapenem-resistant (CR)Klebsiella pneumoniae bacteremia was associated with a 70% rate (23/33) of 30-day survival. Successful treatment was associated with sources of bacteremia amenable to reliable aminoglycoside pharmacokinetics (P = 0.037), acute physiology and chronic health evaluation II (APACHE II) scores of <20 (P = 0.16), and nonfatal underlying diseases (P = 0.015). Success rates were 78% and 100% if ≥2 and all 3 factors were present, respectively. Clinicians may consider the use of aminoglycosides against CRK. pneumoniae bacteremia if strains are susceptible and the sources of infection are amenable to reliable pharmacokinetics.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research